+41 91 682 20 40 info@elixi-int.com

ABOUT US

We are a Swiss pharmaceutical wholesaler, specialized in sourcing and delivering pharma products, medical devices and drugs from and to all over the world.

Here in ELIXI we consider fast delivery of life-saving medicines as a basic but mandatory human value.

 

QUALITY

As a pharmaceutical wholesaler, working directly with pharma manufactures, medicine distributors, hospitals and clinics, we comply with the newest Standard Operating Procedures (SOPs), which guide our professional team step-by-step in all of ELIXI’s activities ensuring the highest quality standards required by the pharma world.

> Read more

 

WHO WE ARE

We deliver pharma products from Switzerland and from all over the world.

Our team in ELIXI International has a solid experience in the distribution of medical products.

History has taught us to prioritize the urgency that lays behind the need of supplying a drug in the fastest possible way. Here in ELIXI we consider fast delivery as a basic but mandatory human value. In order to achieve this goal, we developed a simple but qualified process made of synergies with long lasting partners who, like us, believe in people and not in machines.

 

NEWS

Takhzyro (lanadelumab), a new medicine for hereditary angioedema, a rare disease causing swelling beneath the skin

The European Medicines Agency has recommended granting a marketing authorisation for Takhzyro (lanadelumab), the first monoclonal antibody therapy for the…

read more

Xofluza (baloxavir marboxil), new drug appoved for the treatment of influenza

On October 24th, the U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza…

read more

Pfizer’s Talzenna ( talazoparib) approved for breast cancer.

On October 16, 2018, the Food and Drug Administration approved talazoparib (TALZENNA, Pfizer Inc.), a poly (ADP-ribose) polymerase (PARP) inhibitor,…

read more

U.S. FDA approves Bayer’s Xarelto (rovaroxaban) for patients with coronary or peripheral artery disease

The U.S. Food and Drug Administration (FDA) has approved rivaroxaban (Xarelto), 2.5 mg twice daily, plus aspirin low dose once…

read more

FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old

The U.S. Food and Drug Administration has approved a supplemental application for Gardasil 9 (Human Papillomavirus (HPV) 9-valent Vaccine, Recombinant)…

read more

FDA approves Libtayo (cemiplimab-rwlc) first treatment for advanced form of the second most common skin cancer

The U.S. Food and Drug Administration has approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with…

read more

FDA approves Arikayce (amikacin liposome inhalation suspension), a new antibacterial drug to treat a serious lung disease using a novel pathway to spur innovation.

The U.S. Food and Drug Administration has approved a new drug, Arikayce (amikacin liposome inhalation suspension), for the treatment of…

read more

Luxturna (voretigene neparvovec), first treatment option for hereditary retinal dystrophy with mutations of the RPE65 gene recommended for authorisation by EMA

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for the gene therapy Luxturna…

read more

New monoclonal antibody Emgality ( galcanezumab) for the prevention of migraine

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Emgality (galcanezumab), a monoclonal…

read more

New medicine to treat infections in adults: Vabomere, a combination of an antibiotic and new beta-lactamase inhibitor, addresses bacterial resistance.

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Vabomere (meropenem trihydrate/vaborbactam), a…

read more

Nerlynx, neratinib, a breast cancer medicine used to reduce the risk of the disease coming back in patients with early breast cancer who have had surgery.

Nerlynx is indicated for the extended adjuvant treatment of adult patients with early stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who…

read more

FDA approves Lumoxiti (moxetumomab pasudotox-tdfk), new kind of treatment for hairy cell leukemia

The U.S. Food and Drug Administration has approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult…

read more

CONTACT US

ELIXI International SA

Piazza Boffalora 4
6830 Chiasso / Switzerland

Tel: +41 91 682 20 40

Your name (required)

Your e-mail (required)

Your message

captcha